Key result
HPP-1S suppressed lipid accumulation in oleic acid-treated HepG2 cells and reduced liver damage in high-fat diet-fed rats by modulating AMPK, SREBP1, FAS, Nrf2, and SIRT1.
Why the study?
The study was conducted to investigate the therapeutic effect of the sea urchin gonad-derived polysaccharide HPP-1S on nonalcoholic fatty liver disease.
Does HPP-1S reduce lipid accumulation and liver injury in preclinical models of NAFLD?
Does HPP-1S reduce lipid accumulation and liver injury in preclinical models of NAFLD?
HPP-1S demonstrates potential therapeutic effects for NAFLD by reducing lipid accumulation and liver injury through modulation of AMPK, SIRT1, Nrf2, SREBP1, and FAS pathways in preclinical models.
May support HPP-1S development for steatotic liver disease; hypothesis-generating in animals and should not change practice.
• HPP-1S, which purified from the gonads of sea urchins, has protective effect on OA induced HepG2 cells and HFD-fed rat models. • HPP-1S suppressed lipid accumulation, intracellular TG and LDH levels significantly in HepG2 cells induced by OA. • HPP-1S significantly decreased the lipid content and inhibited liver injury in rats fed a high-fat diet. • HPP-1S treatment increased expressions of AMPK, SIRT1 and Nrf2, and decreased the expressions of SREBP1 and FAS. HPP-1S is a new polysaccharide that was isolated and purified from the gonads of sea urchins in our laboratory. The aim of this study was to investigate the therapeutic effect of the polysaccharide HPP-1S on nonalcoholic fatty liver disease (NAFLD). The results showed that HPP-1S suppressed lipid accumulation in oleic acid (OA)-treated HepG2 cells. In vivo experiments shown that treatment with HPP-1S can reduce lipid accumulation and inhibit liver damage. Further mechanistic investigation indicated that HPP-1S treatment increased the phosphorylation of AMP-activated protein kinase (AMPK). Additionally, the expression of sterol regulatory element-binding protein-1 (SREBP1) and fatty acid synthase (FAS) decreased. After treatment with HPP-1S, the expression of nuclear factor erythroid 2-related factor 2 (Nrf2) and Sirtuin 1 (SIRT1) increased. These results reveal the promising role of HPP-1S in the prevention and treatment of NAFLD. These findings contribute to the development of new therapeutic strategies for the clinical treatment of NAFLD.
No takes yet. Share an insight, caveat, or question.
Liu et al. (2024) studied Nonalcoholic fatty liver disease (NAFLD). HPP-1S was evaluated on Lipid accumulation and liver injury. HPP-1S suppressed lipid accumulation in oleic acid-treated HepG2 cells and reduced liver damage in high-fat diet-fed rats by modulating AMPK, SREBP1, FAS, Nrf2, and SIRT1.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: